Company Filing History:
Years Active: 2010
Title: **Marie Luise Faber: Innovator in Recombinant Rabies Virus Research**
Introduction
Marie Luise Faber, a notable inventor based in Lansdowne, Pennsylvania, has made significant contributions to the field of virology through her innovative research. Her primary patent focuses on recombinant rabies virus compositions, showcasing her efforts to enhance vaccine safety and efficacy. With a passion for scientific advancement, Faber’s work is pivotal in developing nonpathogenic rabies virus variants.
Latest Patents
Marie Luise Faber holds one patent titled "Recombinant Rabies Virus Compositions." This invention revolves around recombinant rabies viruses that have been engineered to exchange the arginine residue of the glycoprotein (G) at amino acid position 333. This exchange renders the viruses nonpathogenic for immunocompetent mammals, regardless of how they are infected. The research indicates that certain recombinant viruses can become pathogenic after serial passages in newborn mice, with the reversion to pathogenicity linked to a specific mutation in the G gene. Faber focused on mutagenesis to minimize the risk of reversion, making strides towards safer rabies vaccines.
Career Highlights
Working at Thomas Jefferson University, Marie Luise Faber has been at the forefront of her research field. Her commitment to scientific inquiry and practical applications has led her to develop solutions that not only advance theoretical knowledge but also have the potential to impact public health positively.
Collaborations
In her impactful research journey, Faber has collaborated with esteemed colleagues such as Bernhard Dietzschold and Matthias Johannes Schnell. These collaborations have enriched her work, allowing for a multidisciplinary approach that enhances the robustness of her inventions and findings.
Conclusion
Marie Luise Faber exemplifies the dedication and innovation necessary for advancing scientific knowledge in virology. Her patent on recombinant rabies virus compositions underscores her efforts to improve vaccine safety, contributing significantly to the public health landscape. Through her collaboration with distinguished peers and her work at Thomas Jefferson University, Faber continues to pave the way for future innovations in the field.